Cargando…
Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum
Current understanding of the mutation spectrum of relapsed/refractory (RR) tumors is limited. We performed whole exome sequencing (WES) on 47 diffuse large B cell lymphoma (DLBCL) tumors that persisted after R-CHOP treatment, 8 matched to primary biopsies. We compared genomic alterations from the RR...
Autores principales: | Greenawalt, Danielle M., Liang, Winnie S., Saif, Sakina, Johnson, Justin, Todorov, Petar, Dulak, Austin, Enriquez, Daniel, Halperin, Rebecca, Ahmed, Ambar, Saveliev, Vladislav, Carpten, John, Craig, David, Barrett, J. Carl, Dougherty, Brian, Zinda, Michael, Fawell, Stephen, Dry, Jonathan R., Byth, Kate |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725088/ https://www.ncbi.nlm.nih.gov/pubmed/29245897 http://dx.doi.org/10.18632/oncotarget.18502 |
Ejemplares similares
-
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity
por: Curtis, Nicola J., et al.
Publicado: (2017) -
GOALs in relapsed DLBCL
por: Rösler, Wiebke, et al.
Publicado: (2022) -
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations
por: Ladd, Brendon, et al.
Publicado: (2016) -
Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020) -
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
por: Hawkes, Eliza A., et al.
Publicado: (2021)